Table 3.

Suppression by P450 inhibitors of tumor formation caused by chemical carcinogens in vivo by in laboratory animals (1)

Inhibitor	Suggested P450 inhibition	Carcinogen administered	Suppression of tumor formation	Reference
a-Naphthoflavone	CYP1	7,12-DMBA, B[a]P	Skin	Gelboin and Kinoshita (53)
	CYP1	7,12-DMBA, B[a]P	Skin	Kinoshita and Gelboin (54)
	CYP1	7,12-DMBA	Skin	Slaga et al. (56)
9-Hydroxyellipticine	CYP1	7,12-DMBA	Skin	Lesca and Mansuy (65)
Benzo[e]pyrene	CYP1	7,12-DMBA	Skin	DiGiovanni et al. (60)
	CYP1	Dibenz[a,h]anthracene	Skin	DiGiovanni et al. (60)
1,2,5,6-Dibenzofluorene		3-MC	Skin	Riegel et al. (57)
		7,12-DMBA	Skin	Hill et al. (58)
1-Ethynylpyrene	CYP1	7,12-DMBA, B[a]P	Skin	Alworth et al. (66)
Imperatorin	CYP1, 2A, 3A	7,12-DMBA, B[a]P	Skin	Cai et al. (67)
Bergamottin	CYP1, 2A 3A	7,12-DMBA	Skin	Kleiner et al. (68)
Isopimpinellin	CYP1, 2A 3A	7,12-DMBA	Skin	Kleiner et al. (68)
Naringenin	CYP1, 2A	7,12-DMBA	Oral	Sulfikkarali et al. (70)
Apigenin	CYP1, 2A	7,12-DMBA	Oral	Silvan et al. (71)
Quercetin	CYP1, 2A	NNK, B[a]P	Lung	Kassie et al. (72)
Hesperidin	CYP2C, 3A	Azoxymethane	Colon	Tanaka et al. (73)
8-Methoxypsoralen	CYP2A	NNK	Lung	Takeuchi et al. (75)
	CYP2A	NNK	Lung	Miyazaki et al. (76)
	CYP2A	NNK	Lung	Takeuchi et al. (77)
	CYP2A	NNK	Lung	Takeuchi et al. (74)
Benzyl isothiocyanate Phenyl isothiocyanate	CYP1, 2A	B[a]P	Lung, stomach	Wattenberg et al. (78)
	CYP2A	NNK	Lung	Morse et al. (79)
	CYP2A	NNK	Lung	Morse et al. (80)
BSC	CYP1, 2A 3A	Azoxymethane	Colon	Fiala et al. (82)
	CYP1, 2A 3A	B[a]P	Stomach	El-Bayoumy (89)
p-XSC, BSC	CYP1, 2A 3A	7,12-DMBA	Mammary	El-Bayaumy et al. (84)
p-XSC	CYP1, 2A 3A	7,12-DMBA	Lung	Prokopczyk et al. (85)
	CYP1, 2A 3A	B[a]P, NNK	Lung	Prokopczyk et al. (86)